NPCE
Neuropace Inc.
Company Overview
| Mkt Cap | $464.98M | Price | $14.35 |
| Volume | 270.26K | Change | +6.30% |
| P/E Ratio | -17.1 | Open | $13.49 |
| Revenue | $79.9M | Prev Close | $13.50 |
| Net Income | $-27.1M | 52W Range | $7.56 - $18.98 |
| Div Yield | N/A | Target | $17.50 |
| Overall | 60 | Value | 40 |
| Quality | -- | Technical | 81 |
No chart data available
About Neuropace Inc.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides Physician Tablet, Patient Data Management System, and nSight Platform, which facilitates ongoing patient monitoring and streamlines patient support. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Latest News
NeuroPace Reports Record Revenue and Raises Guidance
Neuropace, Inc. Advances in Treating Lennox-Gastaut Syndrome: A Study Update
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NPCE | $14.35 | +6.3% | 270.26K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |